Analysts have lowered their fair value estimate for agilon health from $1.55 to approximately $1.22. This change is due to more cautious expectations for revenue growth and profit margins in the updated models.
What's in the News
- On July 29, 2025, the Board amended and restated the by-laws, updating officer designations and reflecting changes in Delaware General Corporation Law (Key Developments).
- agilon health suspended its previously issued full-year 2025 financial guidance, citing leadership changes, ongoing initiatives, and market uncertainty (Key Developments).
- Steven Sell has stepped down as CEO. The Board has begun a search for a permanent replacement with the assistance of an executive search firm (Key Developments).
Valuation Changes
- Fair Value Estimate: Decreased from $1.55 to approximately $1.22. This reflects a notable reduction in the company's assessed worth.
- Discount Rate: Remained unchanged at 6.8%. This suggests the risk profile and return expectations have not shifted.
- Revenue Growth: Lowered from 8.6% to 7.9%. This indicates more cautious expectations for future sales expansion.
- Net Profit Margin: Slightly decreased from 5.4% to 5.3%. This points to a marginally less optimistic outlook for future profitability.
- Future P/E Ratio: Reduced from 1.95x to 1.59x. This shows a decline in anticipated earnings multiples for the company moving forward.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.